New Strategies to Prolong the In Vivo Life Span of Iron-Based Contrast Agents for MRI

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Antonelli, Antonella ^a   Sfara, Carla ^a   Battistelli, Serafina ^a   Canonico, Barbara ^a   Arcangeletti, Marcella ^a   Manuali, Elisabetta ^b   Salamida, Sonia ^b   Papa, Stefano ^a   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL UMBRIA E DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; DRUG CARRIER; FERUCARBOTRAN; HEMOGLOBIN; IRON; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ERYTHROCYTE; FEMALE; HEMATOCRIT; IN VIVO STUDY; MACROPHAGE; MOUSE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR PORE; PHYSICAL CHEMISTRY; PROCESS DEVELOPMENT; RAT; RETICULOENDOTHELIAL SYSTEM; TOXICITY TESTING;

ANIMALS; CONTRAST MEDIA; DEXTRANS; ERYTHROCYTES; FEMALE; HALF-LIFE; HUMANS; KIDNEY; LIVER; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; TISSUE DISTRIBUTION;

EID: 84886411620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078542     Document Type: Article

References (47)

1. Rümenapp C, Gleich B, Haase A, (2012) Magnetic nanoparticles in magnetic resonance imaging and diagnostics. Pharm Res 29: 1165-1179. doi:10.1007/s11095-012-0711-y. PubMed: 22392330.
2. Wang YX, (2011) Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg 1: 35-40. PubMed: 23256052.
3. Neuberger T, Schopf B, Hofmann H, Hofmann M, Von Rechenberg B, (2005) Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater 293: 483-496. doi:10.1016/j.jmmm.2005.01.064.
4. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, et al. (1990) Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175(2):: 489-493. PubMed: 2326474.
5. Bulte JWM, Kraitchman DL, (2004) Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 17(7):: 484-499. doi:10.1002/nbm.924. PubMed: 15526347.
6. Davis SS, (1997) Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. Trends Biotechnol 15(6):: 217-224. doi:10.1016/S0167-7799(97)01036-6. PubMed: 9183864.
7. Berry CC, Curtis ASG, (2003) Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 36(13):: R198-R206. doi:10.1088/0022-3727/36/13/203.
8. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, et al. (1989) Superparamagnetic Iron Oxide: Pharmacokinetics and Toxicity. AJR 152: 167-173. doi:10.2214/ajr.152.1.167. PubMed: 2783272.
9. Kreuter J, (1994) Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet 19(3):: 253-256. doi:10.1007/BF03188928. PubMed: 7867668.
10. Araujo L, Löbenberg R, Kreuter J, (1999) Influence of the surfactant concentration on the body distribution of nanoparticles. J Drug Target 6(5):: 373-385. doi:10.3109/10611869908996844. PubMed: 10342385.
11. Moghimi SM, Hunter AC, Murray JC, (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53(2):: 283-318. PubMed: 11356986.
12. Brigger I, Dubernet C, Couvreur P, (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54(5):: 631-651. doi:10.1016/S0169-409X(02)00044-3. PubMed: 12204596.
13. Corot C, Robert P, Idée JM, Port M, (2006) Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 58: 1471-1504. doi:10.1016/j.addr.2006.09.013. PubMed: 17116343.
14. Veiseh O, Gunn JW, Zhang M, (2010) Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 62: 284-304. doi:10.1016/j.addr.2009.11.002. PubMed: 19909778.
15. Antonelli A, Sfara C, Mosca L, Manuali E, Magnani M, (2008) New biomimetic constructs for improved in vivo circulation of superparamagnetic nanoparticles. J Nanosci Nanotechnol 8: 2270-2278. doi:10.1166/jnn.2008.190. PubMed: 18572637.
16. Magnani M, Pierigè F, Rossi L, (2012) Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acid-based therapeutics. Ther Deliv 3: 405-414. doi:10.4155/tde.12.6. PubMed: 22833997.
17. Antonelli A, Sfara C, Manuali E, Bruce IJ, Magnani M, (2011) Encapsulation of superparamagnetic nanoparticles into red blood cells as new carriers of MRI contrast agents. Nanomedicine (Lond) 6: 211-223. doi:10.2217/nnm.10.163. PubMed: 21385124.
18. Markov DE, Boeve H, Gleich B, Borgert J, Antonelli A, et al. (2010) Human erythrocytes as nanoparticle carriers for magnetic particle imaging. Phys Med Biol 55: 6461-6473. doi:10.1088/0031-9155/55/21/008. PubMed: 20959685.
19. Antonelli A, Sfara C, Magnani M, Rahmer J, Gleich B, et al. (2012) Red Blood Cells as Magnetic Carriers for MPI Applications. Springer Proceeding in Physics 140. Buzug TM, Borgert J, eds. MAGNETIC PARTICLE IMAGING A Novel SPIO Nanoparticle Imaging Technique 1st Edition. Lubeck, Germany, 15-16 March(2012). pp. pp. 175-179.
20. Rahmer J, Antonelli A, Sfara C, Tiemann B, Gleich B, et al. (2013) Nano-particle encapsulation in red blood cells enables blood-pool magnetic particle imaging hours after injection. Phys Med Biol 58: 3965-3977. doi:10.1088/0031-9155/58/12/3965. PubMed: 23685712.
21. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, et al. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448. doi:10.1126/science.7939685. PubMed: 7939685.
22. Selander KS, Mönkkönen J, Karhukorpi EK, Härkönen P, Hannuniemi R, et al. (1996) Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50: 1127-1138. PubMed: 8913344.
23. Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ, (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44: 2201-2210. doi:10.1002/1529-0131(200109)44:9. PubMed: 11592386.
24. Jun YW, Lee JH, Cheon J, (2008) Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl 47: 5122-5135. doi:10.1002/anie.200701674. PubMed: 18574805.
25. Wang YX, Hussain SM, Krestin GP, (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11: 2319-2331. doi:10.1007/s003300100908. PubMed: 11702180.
26. Zhang C, Liu T, Gao J, Su Y, Shi C, (2010) Recent development and application of magnetic nanoparticles for cell labeling and imaging. Mini Rev Med Chem 10: 193-202. PubMed: 20408802.
27. Gadian DG, (1984) Nuclear Magnetic Resonance and its Applications to Living Systems. Oxford, UK: The Alden Press Ltd.
28. Carr HY, Purcell EM, (1954) Effects of diffusion on free precession in nuclear magnetic resonance experiments. Phys Rev 94: 630-638. doi:10.1103/PhysRev.94.630.
29. Meiboom S, Gill D, (1958) Modified spin-echo method for measuring nuclear relaxation times. Rev Sci Instrum 29: 688-691. doi:10.1063/1.1716296.
30. Austyn JM, Gordon S, (1981) F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11: 805-815. doi:10.1002/eji.1830111013. PubMed: 7308288.
31. Corot C, Violas X, Philippe R, Gagneur G, Port M, (2003) Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol. Invest Radiol 38: 311-319. doi:10.1097/01.rli.0000066814.82006.be. PubMed: 12908698.
32. Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P, (2002) Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology 223: 432-438. doi:10.1148/radiol.2232010241. PubMed: 11997549.
33. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, et al. (2007) Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 13: 95-99. doi:10.1038/nm1467. PubMed: 17187073.
34. Brähler M, Georgieva R, Buske N, Müller A, Müller S, et al. (2006) Magnetite-Loaded Carrier Erythrocytes as Contrast Agents for Magnetic Resonance Imaging. Nano Lett 6: 2505-2509. doi:10.1021/nl0618501. PubMed: 17090081.
35. Sprandel U, Lanz DJ, von Hörsten W, (1987) Magnetically responsive erythrocyte ghosts. Methods Enzymol 149: 301-312. doi:10.1016/0076-6879(87)49068-X. PubMed: 3695966.
36. Vyas SP, Jain SK, (1994) Preparation and in vitro characterization of a magnetically responsive ibuprofen-loaded erythrocytes carrier. J Microencapsul 11: 19-29. doi:10.3109/02652049409040435. PubMed: 8138871.
37. Boni A, Ceratti D, Antonelli A, Sfara C, Magnani M, et al. (2013) USPIO-loaded Red Blood Cells as a biomimetic MR contrast agent: a relaxometric study. Contrast Media & Molecular Imaging, in press.
38. DeLoach JR, (1987) Dialysis method for entrapment of proteins into resealed red blood cells. Methods Enzymol 149: 235-242. doi:10.1016/0076-6879(87)49061-7. PubMed: 3320681.
39. Zhu H, Zennadi R, Xu BX, Eu JP, Torok JA, et al. (2011) Impaired ATP release from red blood cells promotes their adhesion to endothelial cells: A mechanism of hypoxemia after transfusion. Crit Care Med 39(11):: 2478-2486. doi:10.1097/CCM.0b013e318225754f. PubMed: 21765360.
40. Castro O, Orlin J, Rosen MW, Finch SC, (1973) Survival of Human Sickle-Cell Erythrocytes in Heterologous Species: Response to Variations in Oxygen Tension. Proc Natl Acad Sci U S A 70(8):: 2356-2359. doi:10.1073/pnas.70.8.2356. PubMed: 4525428.
41. Mönkkönen J, Urtti A, Paronen P, Elo HA, Ylitalo P, (1989) The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro. Drug Metab Dispos 17(6):: 690-693. PubMed: 2575509.
42. Rossi L, Serafini S, Antonelli A, Pierigé F, Carnevali A, et al. (2005) Macrophage depletion induced by clodronate-loaded erythrocytes. J Drug Target 13: 99-111. doi:10.1080/10611860500064123. PubMed: 15823961.
43. Van Rooijen N, Kors N, Kraal G, (1989) Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol 45: 97-104. PubMed: 2521666.
44. Westermann J, Ronneberg S, Fritz FJ, Pabst R, (1989) Proliferation of macrophage subpopulations in the adult rat: a comparison of various lymphoid organs. J Leukoc Biol 46: 263-269. PubMed: 2788207.
45. Van Rooijen N, Kors N, v.d. Ende M, Dijkstra CD, (1990) Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell and Tissue Research 260(2):: 215-222.
46. Cambos M, Scorza T, (2011) Robust erythrophagocytosis leads to macrophage apoptosis via a hemin-mediated redox imbalance: role in hemolytic disorders. J Leukoc Biol 89: 159-171. doi:10.1189/jlb.0510249. PubMed: 20884648.
47. Zhao X, Grotta J, Gonzales N, Aronowski J, (2009) Hematoma Resolution as a Therapeutic Target: The Role of Microglia/Macrophages. Stroke 40 (suppl.1) []:: S92-S94. doi:10.1161/STROKEAHA.108.533158. PubMed: 19064796.